M MIRUM PHARMACEUTICALS INC
| Market Cap | $5.68B |
| P/E Ratio | — |
| Forward P/E | -867.37 |
| Dividend Yield | — |
| Beta | 0.52 |
| 52W Range | $38.39 - $108.62 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $1.05M | 13,360 | Add 0.16% |
Insider Trading
| Insider Name of the company insider who made the trade 33 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| BJERKHOLT ERICCHIEF FINANCIAL OFFICER | Sale | 7,287 | $91.98 | $670.24K | 16 Mar 2026 | 15 Mar 2026 |
| Radovich PeterPRESIDENT AND COO | Sale | 16,515 | $91.98 | $1.52M | 16 Mar 2026 | 15 Mar 2026 |
| Quan JoanneCHIEF MEDICAL OFFICER | Sale | 7,287 | $91.98 | $670.24K | 16 Mar 2026 | 15 Mar 2026 |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER | Sale | 40,985 | $91.98 | $3.77M | 16 Mar 2026 | 15 Mar 2026 |
| Howe JolandaSVP, GLOBAL CONTROLLER | Sale | 4,732 | $91.98 | $435.24K | 16 Mar 2026 | 15 Mar 2026 |
| Ramasastry Saira | Sale | 2,000 | $90.76 | $181.52K | 16 Mar 2026 | 16 Mar 2026 |
| Ramasastry Saira | Sale | 2,000 | $102.09 | $204.18K | 13 Feb 2026 | 17 Feb 2026 |
| Radovich PeterPRESIDENT AND COO | Sale | 2,631 | $103.30 | $271.79K | 02 Feb 2026 | 03 Feb 2026 |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER | Sale | 9,108 | $103.30 | $940.89K | 02 Feb 2026 | 03 Feb 2026 |
| Howe JolandaSVP, GLOBAL CONTROLLER | Sale | 968 | $103.30 | $100.00K | 02 Feb 2026 | 03 Feb 2026 |
| Peter RadovichPRESIDENT AND COO | Sale | 2,631 | $103.30 | $271.79K | 02 Feb 2026 | 03 Feb 2026 |
| Christopher PeetzCHIEF EXECUTIVE OFFICER | Sale | 9,108 | $103.30 | $940.89K | 02 Feb 2026 | 03 Feb 2026 |
| Jolanda HoweSVP, GLOBAL CONTROLLER | Sale | 968 | $103.30 | $100.00K | 02 Feb 2026 | 03 Feb 2026 |
| Radovich PeterPRESIDENT AND COO | Sale | 3,143 | $96.19 | $302.33K | 26 Jan 2026 | 27 Jan 2026 |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER | Sale | 6,831 | $96.19 | $657.09K | 26 Jan 2026 | 27 Jan 2026 |
| BJERKHOLT ERICCHIEF FINANCIAL OFFICER | Sale | 1,053 | $96.19 | $101.29K | 26 Jan 2026 | 27 Jan 2026 |
| Howe JolandaSVP, GLOBAL CONTROLLER | Sale | 842 | $96.19 | $80.99K | 26 Jan 2026 | 27 Jan 2026 |
| Heron Patrick J | Buy | 131,425 | $68.48 | $9.00M | 23 Jan 2026 | 27 Jan 2026 |
| Howe JolandaSVP, GLOBAL CONTROLLER | Sale | 926 | $93.33 | $86.42K | 22 Jan 2026 | 23 Jan 2026 |
| BJERKHOLT ERICCHIEF FINANCIAL OFFICER | Sale | 1,421 | $93.33 | $132.62K | 22 Jan 2026 | 23 Jan 2026 |
| Radovich PeterPRESIDENT AND COO | Sale | 2,382 | $93.33 | $222.30K | 22 Jan 2026 | 23 Jan 2026 |
| Quan JoanneCHIEF MEDICAL OFFICER | Sale | 1,822 | $93.33 | $170.04K | 22 Jan 2026 | 23 Jan 2026 |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER | Sale | 7,098 | $93.33 | $662.42K | 22 Jan 2026 | 23 Jan 2026 |
| Quan JoanneCHIEF MEDICAL OFFICER | Sale | 6,911 | $90.27 | $623.85K | 20 Jan 2026 | 21 Jan 2026 |
| Ramasastry Saira | Sale | 2,000 | $90.99 | $181.98K | 15 Jan 2026 | 16 Jan 2026 |
| Ramasastry Saira | Sale | 5,000 | $80.00 | $400.00K | 22 Dec 2025 | 23 Dec 2025 |
| GREY MICHAEL G | Sale | 50,000 | $78.00 | $3.90M | 19 Dec 2025 | 23 Dec 2025 |
| Ramasastry Saira | Sale | 1,000 | $70.00 | $70.00K | 18 Dec 2025 | 19 Dec 2025 |
| Ramasastry Saira | Sale | 1,000 | $69.46 | $69.46K | 18 Dec 2025 | 19 Dec 2025 |
| GREY MICHAEL G | Sale | 50,000 | $74.00 | $3.70M | 01 Dec 2025 | 02 Dec 2025 |
| Michael G GreyDirector | Sale | 50,000 | $74.00 | $3.70M | 01 Dec 2025 | 02 Dec 2025 |
| GREY MICHAEL G | Sale | 50,000 | $70.00 | $3.50M | 21 Nov 2025 | 25 Nov 2025 |
| Michael G GreyDirector | Sale | 50,000 | $70.00 | $3.50M | 21 Nov 2025 | 25 Nov 2025 |
Frequently Asked Questions
What is MIRM stock price today?
MIRUM PHARMACEUTICALS INC (MIRM) is currently trading at $94.17. The stock has a 52-week range of $38.39 to $108.62 and a market capitalization of $5.68B.
Is MIRM a good stock to buy in 2026?
MIRUM PHARMACEUTICALS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +117.8%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling MIRM stock?
There have been 33 insider transactions for MIRM in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has MIRM stock performed over the past year?
MIRUM PHARMACEUTICALS INC (MIRM) has returned +117.8% over the past 12 months. The stock traded between $38.39 and $108.62 during this period, and is currently at $94.17.
Which hedge funds own MIRM (MIRUM PHARMACEUTICALS INC)?
1 tracked hedge funds currently hold MIRM in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is MIRM's market cap and valuation?
MIRUM PHARMACEUTICALS INC (MIRM) has a market capitalization of $5.68B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is MIRM's revenue and profitability?
MIRUM PHARMACEUTICALS INC reported revenue of $521.31M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.52.
What sector is MIRM in and who are its biggest institutional holders?
MIRUM PHARMACEUTICALS INC (MIRM) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.